logo

Abbvie (ABBV)



Trade ABBV now with
  Date
  Headline
5/27/2022 3:32:15 AM The Lancet Publishes Results From Phase 3 Induction & Maintenance Programs Evaluating Upadacitinib In Ulcerative Colitis
5/27/2022 3:03:03 AM The Lancet Publishes Results From Phase 3 Induction And Maintenance Programs Evaluating Risankizumab In Crohn's Disease
5/24/2022 8:01:53 AM AbbVie : KEEPsAKE 1 & 2 Trials Showcase The Efficacy And Safety Data Of SKYRIZI N Patients With Active PsA
5/23/2022 8:03:20 AM AbbVie Presents Positive Data From Phase 3 Study Of Cariprazine For Adjunctive Treatment Of MDD At APA Annual Meeting
5/23/2022 2:14:08 AM AbbVie : CHMP Recommends EC Approval Of Upadacitinib For Treatment Of Moderate To Severe Ulcerative Colitis
5/20/2022 8:20:31 AM AbbVie Submits NDA To FDA For ABBV-951 For Treatment Of Advanced Parkinson's Disease
5/16/2022 7:35:28 AM AbbVie And Cugene Announce Exclusive Worldwide License Option Agreement For CUG252
5/11/2022 8:47:54 AM AbbVie Announces Positive Results From Phase 3 Study Of Upadacitinib In Moderate To Severe Crohn's Disease
4/29/2022 8:03:10 AM AbbVie Q1 Income Rises
4/29/2022 8:00:44 AM AbbVie (ABBV) Has Lowered Its 2022 EPS Estimate To 13.92 - 14.12 From 14.00 - 14.20
4/29/2022 7:50:05 AM AbbVie Q1 GAAP EPS $2.51; Adj EPS $3.16
4/28/2022 8:03:01 AM Abbvie And Plexium To Develop And Commercialize Targeted Protein Degradation Therapies For Neurological Conditions